CBER Director Peter Marks (Greg Nash/Pool via AP Images)
Following CAR-T safety label changes, FDA officials share new details about secondary cancer cases
More than half of the cancer cases the FDA is examining as part of its CAR-T safety investigation occurred within two years of treatment, according …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
